Hye-Jung Kim
Overview
Explore the profile of Hye-Jung Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
5408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Lee H, Jang Y, Lee K, Kim H, Lee J, et al.
Mol Med
. 2024 Dec;
30(1):248.
PMID: 39701944
Background: Bone remodeling is a critical process that maintains skeletal integrity, orchestrated by the balanced activities of osteoclasts, which resorb bone, and osteoblasts, which form bone. Osteoclastogenesis, the formation of...
2.
Kim M, Choi H, Jang D, Kim H, Sub Y, Gee H, et al.
Stem Cells Transl Med
. 2024 Jun;
13(7):637-647.
PMID: 38838263
Extracellular vesicles, particularly exosomes, have emerged as promising drug delivery systems owing to their unique advantages, such as biocompatibility, immune tolerability, and target specificity. Various engineering strategies have been implemented...
3.
Kim H, Choi J, Seong D, Jeong J, Kim H, Park S, et al.
Vet Sci
. 2024 Jan;
11(1).
PMID: 38250935
The bluetongue virus (BTV) is a significant animal pathogen with economic implications in the ruminant industry. Despite global reports on BTV detection and epidemiologic investigations, limited studies have focused on...
4.
Kim H, Nakagawa H, Choi J, Che X, Divris A, Liu Q, et al.
J Clin Invest
. 2023 Nov;
134(1).
PMID: 37934601
Although most CD8+ T cells are equipped to kill infected or transformed cells, a subset may regulate immune responses and preserve self-tolerance. Here, we describe a CD8 lineage that is...
5.
Bergholz J, Wang Q, Wang Q, Ramseier M, Prakadan S, Wang W, et al.
Nature
. 2023 Apr;
617(7959):139-146.
PMID: 37076617
Loss of the PTEN tumour suppressor is one of the most common oncogenic drivers across all cancer types. PTEN is the major negative regulator of PI3K signalling. The PI3Kβ isoform...
6.
Qiu Y, Shen X, Ravid O, Atrakchi D, Rand D, Wight A, et al.
Proc Natl Acad Sci U S A
. 2023 Feb;
120(6):e2218915120.
PMID: 36730200
Alzheimer's disease (AD) is the most common form of incurable dementia and represents a critical public health issue as the world's population ages. Although microglial dysregulation is a cardinal feature...
7.
Ding L, Wang Q, Martincuks A, Kearns M, Jiang T, Lin Z, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36609487
Background: Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic....
8.
Sa S, Seol Y, Lee A, Heo Y, Kim H, Park C
Toxicol Rep
. 2022 Dec;
9:821-824.
PMID: 36518485
The objective of this study was to evaluate whether D-allulose has teratogenic effects on rats. A prenatal developmental toxicity test was conducted in SD rats in compliance with modified OECD...
9.
Lee D, Kim H, Park M, Hong J, Ryoo S
J Infect
. 2022 Aug;
85(5):e137-e139.
PMID: 35987390
No abstract available.
10.
Wang Q, Bergholz J, Ding L, Lin Z, Kabraji S, Hughes M, et al.
Nat Commun
. 2022 May;
13(1):3022.
PMID: 35641483
PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in patients with advanced BRCA-mutant breast...